Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Efgartigimod Alfa · Vyvgart, ARGX-113

Fusion protein · Inhibitor of neonatal Fc receptor (FCGRT) · developed by Argenx Bv

Approved FDA, Dec 2021
ARGX Developer
3 Registered trials

What is Efgartigimod Alfa?

Efgartigimod alfa is a human IgG1-derived Fc fragment that binds the neonatal Fc receptor (FcRn) and blocks it from recycling IgG back into the circulation, reducing circulating IgG levels, including pathogenic autoantibodies. It is studied in myasthenia gravis, optic neuritis, and epidermolysis bullosa.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Vyvgart, ARGX-113, efgartigimod administration, Vyvgart Hytrulo, Efgartigimod
Drug type
Fusion protein
Targets
neonatal Fc receptor (FCGRT)
Mechanism
Inhibitor of neonatal Fc receptor (FCGRT)
Pathways
IgG recycling, IgG degradation
Therapy area
Dermatology, Neurology, Ophthalmology
Developer
Argenx Bv (ARGX)
FDA status
Approved as Vyvgart (December 17, 2021), BLA761195 · FDA label
UNII
961YV2O515

✅ FDA-approved uses

From the indications section of the FDA label (version of May 13, 2026). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT06765161 Phase 3 Myasthaenia Gravis Recruiting ARGX
NCT07011589 Phase 1/2 Epidermolysis Bullosa (EB) Not yet recruiting ARGX
NCT06453694 Phase 2 Optic Neuritis Recruiting ARGX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Dystrophic Epidermolysis BullosaEpidermolysis Bullosa (EB)Epidermolysis Bullosa AcquisitaMyasthaenia GravisOptic NeuritisRecessive Dystrophic Epidermolysis Bullosa

Other drugs acting on FCGRT

More from Argenx Bv

Sources

Updated Nov 8, 2026. Something wrong or missing? Report it on the ARGX page.

Follow ARGX, the company behind Efgartigimod Alfa

See ARGX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

ARGX catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.